YD Bio Limited Reports Unaudited Financial Results for the Six Months Ended June 30, 2026

YD Bio (Nasdaq: YDES), a biotechnology company focused on DNA methylation-based cancer detection and ophthalmologic innovations, announced H1 2026 results showing 315% revenue growth to $846.5 million and net income of $6.7 million. The profitability was primarily driven by a $9.8 million non-cash gain from warrant liability fair value changes. Excluding this adjustment, the company reported an operational net loss of $3.1 million. Revenue growth was fueled by large orders including a $327 million Fetroja order, though gross margins were pressured by lower-margin sales. The company is expanding its laboratory network, advancing exosome manufacturing, and pursuing strategic acquisitions while managing cash burn.

08/31/2026, 6:00 PM • GlobeNewswire

YD Bio Expands U.S. Laboratory Footprint to 46 States, Strengthening DNA-Methylation Early Cancer Detection Operations

YD Bio announced that its affiliate EG BioMed US obtained out-of-state clinical laboratory licenses in Rhode Island and Pennsylvania, expanding its CLIA-certified laboratory's authorized operating footprint to 46 U.S. states plus Washington D.C. and Guam. The expansion supports the company's DNA methylation-based early cancer detection operations and broadens patient access to blood-based testing services for various cancers.

07/02/2026, 8:00 AM • GlobeNewswire

YD Bio Limited Reports Full Year 2025 Financial Results

YD Bio (Nasdaq: YDES) announced full-year 2025 financial results showing 17% net revenue increase to $596.8 million, driven by pharmaceutical sales growth and new product launches. However, the company reported a net loss of $8.3 million compared to $1.4 million in 2024, primarily due to a $3.2 million change in warrant liabilities and increased operating expenses from business expansion. The company ended 2025 with $6.0 million in cash and outlined 2026 strategic priorities including FDA submissions for its Limbal Stem Cell platform and pancreatic cancer detection program, along with planned M&A activities.

04/30/2026, 6:00 PM • GlobeNewswire

YD Bio Limited Expands U.S. Presence with Newly Planned California Facilities and Operations Center

YD Bio Limited plans to establish a new U.S. operations center in California to accelerate clinical development, regulatory engagement, and commercial access for cancer diagnostics and exosome-based therapeutics.

12/16/2025, 9:00 AM • GlobeNewswire